For the first quarter of the fiscal year ending March 2027, consolidated results: net sales 11,003 million yen (YoY +0.7%), operating income 546 million yen (YoY +19.9%), ordinary income 637 million yen (YoY +18.8%), and net income attributable to owners of parent 385 million yen (YoY +20.2%). The Clinical Testing segment led performance, while the Dispensing Pharmacy segment saw a decline in sales due to a reduction in store count; ICT remained solid but costs increased. The full-year forecast is unchanged from the prior outlook.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4671","jir_company_name":"Falco Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4671-20260805-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending March 2027, consolidated results: net sales 11,003 million yen (YoY +0.7%), operating income 546 million yen (YoY +19.9%), ordinary income 637 million yen (YoY +18.8%), and net income attributable to owners of parent 385 million yen (YoY +20.2%). The Clinical Testing segment led performance, while the Dispensing Pharmacy segment saw a decline in sales due to a reduction in store count; ICT remained solid but costs increased. The full-year forecast is unchanged from the prior outlook.","jir_summary":"### Business Performance Overview\nFor the first quarter of the fiscal year ending March 2027, total net sales amounted to 11,003 million yen, up 0.7% YoY. Growth in the Clinical Testing segment drove overall performance, with operating income of 546 million yen, up 19.9% YoY; ordinary income of 637 million yen, up 18.8% YoY; and quarterly net income attributable to owners of parent of 385 million yen, up 20.2% YoY. By segment, Clinical Testing remained solid, Dispensing Pharmacy declined 1.3% due to decreased store count, and ICT rose 15.5%. The full-year outlook remains as previously announced.\n\n### Financial Position and Outlook\nAs of quarter-end, total assets were 37,127 million yen, net assets were 25,383 million yen, and the equity ratio was 68.2%. Cash and deposits totaled 8,684 million yen, current assets were 18,649 million yen, current liabilities were 8,477 million yen, and total liabilities were 11,743 million yen. The second-quarter cumulative forecast was not disclosed. In the long term, the Company will continue to promote foundational and growth businesses under the FALCO VISION 2030 and FALCO INNOVATION 2026 plans.","jir_financial_highlights":"Net sales: 11,003\u767e\u4e07\u5186 (YoY +0.7%)\nOperating income: 546\u767e\u4e07\u5186 (YoY +19.9%)\nOrdinary income: 637\u767e\u4e07\u5186 (YoY +18.8%)\nNet income attributable to owners of parent: 385\u767e\u4e07\u5186 (YoY +20.2%)\nSegment net sales_Clinical Testing: 6,939\u767e\u4e07\u5186 (YoY +1.1%)\nSegment net sales_Dispensing Pharmacy: 3,694\u767e\u4e07\u5186 (YoY -1.3%)\nSegment net sales_ICT: 368\u767e\u4e07\u5186 (YoY +15.5%)","jir_category":"","jir_hashtags":"#FalcoHoldings, #financial_summary, #JapanStocks","jir_key_figures":"Net sales: 11,003\u767e\u4e07\u5186\uff08YoY +0.7%\uff09\nOperating income: 546\u767e\u4e07\u5186\uff08YoY +19.9%\uff09\nOrdinary income: 637\u767e\u4e07\u5186\uff08YoY +18.8%\uff09","jir_meta_title":"Falco Holdings | Q1 FY2027 Consolidated Results: Net Sales 11,003 million yen, Operating Income 546 million yen","jir_meta_description":"Summary of Falco Holdings' Q1 FY2027 consolidated results. Highlights include solid Clinical Testing, reduced Dispensing Pharmacy impact, and ICT growth; full-year guidance unchanged.","jir_og_title":"Falco HD Announces Q1 FY2027 Consolidated Results","jir_og_description":"Clinical testing leads, dispensing pharmacies shrink, ICT grows. Full-year guidance unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57353,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95841","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n